Comparison of Adjuvant Therapies by an H2‐receptor Antagonist and a Proton Pump Inhibitor After Endoscopic Treatment in Hemostatic Management of Bleeding Gastroduodenal Ulcers

Sakurada, Tomoya; Kawashima, Junichi; Ariyama, Shigekazu; Kani, Kazuhito; Takabayashi, Hidehiko; Ohno, Shino; Kato, Shingo; Yakabi, Koji

doi:10.1111/j.1443-1661.2011.01176.x

Cited by 8 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PPI (pantoprazole, omeprazole) versus i.v. H2RA (ranitidine, famotidine) after endoscopic therapy showed no significant differences in the rate of rebleeding . However, other studies have shown that PPI is superior to H2RA in reducing the rebleeding rate, the need for blood transfusion, and duration of hospitalization .…”

Section: Management Of Patients With Acute Peptic Gastroduodenal Ulcementioning

confidence: 94%

“…H2RA (ranitidine, famotidine) after endoscopic therapy showed no significant differences in the rate of rebleeding. [116][117][118][119] However, other studies have shown that PPI is superior to H2RA in reducing the rebleeding rate, the need for blood transfusion, and duration of hospitalization. 120,121 Different hemostatic methods or different dose of PPI may have affected the different outcomes.…”

Section: Management After Successful Endoscopic Hemostasismentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for endoscopic management of non‐variceal upper gastrointestinal bleeding

Fujishiro

Iguchi

Kakushima

et al. 2016

Digestive Endoscopy

View full text Add to dashboard Cite

Japan Gastroenterological Endoscopy Society (JGES) has compiled a set of guidelines for endoscopic management of non‐variceal upper gastrointestinal bleeding using evidence‐based methods. The major cause of non‐variceal upper gastrointestinal bleeding is peptic gastroduodenal ulcer bleeding. As a result, these guidelines mainly focus on peptic gastroduodenal ulcer bleeding, although bleeding from other causes is also overviewed. From the epidemiological aspect, in recent years in Japan, bleeding from drug‐related ulcers has become predominant in comparison with bleeding from Helicobacter pylori (HP)‐related ulcers, owing to an increase in the aging population and coverage of HP eradication therapy by national health insurance. As for treatment, endoscopic hemostasis, in which there are a variety of methods, is considered to be the first‐line treatment for bleeding from almost all causes. It is very important to precisely evaluate the severity of the patient's condition and stabilize the patient's vital signs with intensive care for successful endoscopic hemostasis. Additionally, use of antisecretory agents is recommended to prevent rebleeding after endoscopic hemostasis, especially for gastroduodenal ulcer bleeding. Eighteen statements with evidence and recommendation levels have been made by the JGES committee of these guidelines according to evidence obtained from clinical research studies. However, some of the statements that are supported by a low level of evidence must be confirmed by further clinical research.

show abstract

Section: Management Of Patients With Acute Peptic Gastroduodenal Ulcementioning

confidence: 94%

Section: Management After Successful Endoscopic Hemostasismentioning

confidence: 99%

Guidelines for endoscopic management of non‐variceal upper gastrointestinal bleeding

Fujishiro

Iguchi

Kakushima

et al. 2016

Digestive Endoscopy

View full text Add to dashboard Cite

show abstract

“…However, there has been no significant difference in efficacy after endoscopic treatment for hemorrhagic peptic ulcers between intravenous PPI and H 2 RA therapy in Japan [14]. The reasons for this difference between foreign counties and Japan were thought to be as follows: (1) PPIs are usually administered in foreign countries at twice the dose as in Japan; and (2) endoscopic hemostatic techniques are better in Japan than in foreign countries.…”

Section: Non-endoscopic Therapymentioning

confidence: 99%

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology (JSGE) revised the evidence-based clinical practice guidelines for peptic ulcer disease in 2014 and has created an English version. The revised guidelines consist of seven items: bleeding gastric and duodenal ulcers, Helicobacter pylori (H. pylori) eradication therapy, non-eradication therapy, drug-induced ulcer, non-H. pylori, non-nonsteroidal anti-inflammatory drug (NSAID) ulcer, surgical treatment, and conservative therapy for perforation and stenosis. Ninety clinical questions (CQs) were developed, and a literature search was performed for the CQs using the Medline, Cochrane, and Igaku Chuo Zasshi databases between 1983 and June 2012. The guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Therapy is initially provided for ulcer complications. Perforation or stenosis is treated with surgery or conservatively. Ulcer bleeding is first treated by endoscopic hemostasis. If it fails, surgery or interventional radiology is chosen. Second, medical therapy is provided. In cases of NSAID-related ulcers, use of NSAIDs is stopped, and anti-ulcer therapy is provided. If NSAID use must continue, the ulcer is treated with a proton pump inhibitor (PPI) or prostaglandin analog. In cases with no NSAID use, H. pylori-positive patients receive eradication and anti-ulcer therapy. If first-line eradication therapy fails, second-line therapy is given. In cases of non-H. pylori, non-NSAID ulcers or H. pyloripositive patients with no indication for eradication therapy, non-eradication therapy is provided. The first choice is PPI therapy, and the second choice is histamine 2-receptor antagonist therapy. After initial therapy, maintenance therapy is provided to prevent ulcer relapse.

show abstract

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding

Kanno

Yuan

Tse

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Comparison of Adjuvant Therapies by an H2‐receptor Antagonist and a Proton Pump Inhibitor After Endoscopic Treatment in Hemostatic Management of Bleeding Gastroduodenal Ulcers

Abstract: Famotidine and omeprazole injected during the early phase of a bleeding ulcer may have similar effects to an adjuvant therapy for preventing rebleeding from endoscopically treated upper gastrointestinal bleeding in Japanese patients.

Cited by 8 publications

References 33 publications

Guidelines for endoscopic management of non‐variceal upper gastrointestinal bleeding

Guidelines for endoscopic management of non‐variceal upper gastrointestinal bleeding

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding

Contact Info

Product

Resources

About